Professor Colin Baigent
- Anaemic heart failure: factors associated with progression from severe morbidity to death among pregnant women in India
- Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU)
- Individual patient meta-analyses of randomized trials of aspirin for the primary prevention of cardiovascular disease (MRC PHRU)
- Medical Research Council Population Health Research Unit (MRC PHRU)
Professor of Epidemiology and Director, MRC PHRU
- Deputy Director, CTSU
Colin Baigent studied Medicine at Bristol and Oxford University (1983-89), having originally studied Mathematics at Oxford (1980-83).
He became an MRC career scientist in 2002, and in 2006 was appointed Professor of Epidemiology at Oxford. From July 2013, he became Deputy Director of CTSU.
His main interest is in cardiovascular epidemiology, and most particularly the design, conduct and application of large-scale randomised trials in cardiovascular disease. His research includes the coordination of meta-analyses of randomised trials, typically with individual participant data, resulting in landmark papers that have helped determine the effects of aspirin (and other antiplatelet drugs), non-steroidal anti-inflammatory drugs, fibrinolytic therapy, and statins in different types of patients. His group has also contributed to a better understanding of cardiovascular disease in patients with renal impairment through the Study of Heart and Renal Protection (SHARP), the largest ever in patients with moderate-to-severe chronic kidney disease (CKD), recruiting 9438 patients in nearly 400 hospitals in 18 countries.
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
HALLIDAY A. et al, (2019), For Presentation at the European Society of Cardiology on 2nd September 2019
Variability in aspirin efficacy: all in the genes?
Baigent C. and Holmes MV., (2019), Eur Heart J
Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial.
RESTART Collaboration None., (2019), Lancet (London, England), 393, 2613 - 2623
Chronic kidney disease, heart failure and neprilysin inhibition.
Haynes R. et al, (2019), Nephrol Dial Transplant
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Schlackow I. et al, (2019), Kidney Int